Neeta Pandit-Taskar

List of Publications by Year
in descending order

93 papers	4,518 citations	109321 35 h-index	110387 64 g-index
95 all docs	95 docs citations	95 times ranked	5366 citing authors

#	Article	IF	Citations
1	ImmunoPET: harnessing antibodies for imaging immune cells. Molecular Imaging and Biology, 2022, 24, 181-197.	2.6	15
2	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2022, 21, 125-137.	4.1	5
3	Radiation Safety Considerations and Clinical Advantages of Î±-Emitting Therapy Radionuclides. Journal of Nuclear Medicine Technology, 2022, 50, 10-16.	0.8	2
4	Biodistribution and Radiation Dosimetry of Intraperitoneally Administered ¹²⁴I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors. Journal of Nuclear Medicine, 2022, 63, 1094-1100.	5.0	2
5	F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. Journal of Nuclear Cardiology, 2022, 29, 3179-3188.	2.1	7
6	Molecular Immune Targeted Imaging of Tumor Microenvironment. Nanotheranostics, 2022, 6, 286-305.	5.2	11
7	Imaging in malignant adrenal cancers. , 2022, , .		0
8	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2300-2309.	6.4	20
9	Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device. Journal of Neuro-Oncology, 2022, 157, 457-463.	2.9	1
10	Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 2022, 28, 2030-2037.	7.0	21
11	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Journal of Nuclear Medicine, 2022, 63, 1836-1843.	5.0	5
12	IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamabâ€"pharmacokinetic modeling to optimize therapeutic index. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1166-1177.	6.4	9
13	Novel Agents and Future Perspectives on Theranostics. Seminars in Radiation Oncology, 2021, 31, 83-92.	2.2	9
14	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2642-2651.	6.4	26
15	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET. Clinical Cancer Research, 2021, 27, 1958-1966.	7.0	21
16	A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document. International Journal of Radiation Oncology Biology Physics, 2021, 109, 913-922.	0.8	12
17	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2021, 27, 2989-2995.	7.0	42
18	CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. Journal of Nuclear Medicine, 2021, , jnumed.121.262485.	5.0	49

#	Article	IF	Citations
19	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 447-456.	1.9	3
20	FDG PET/CT imaging features and clinical utility in COVID-19. Clinical Imaging, 2021, 80, 262-267.	1.5	8
21	Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 4810-4810.	1.4	1
22	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Journal of Nuclear Medicine, 2021, 62, 12S-22S.	5.0	14
23	Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. Journal of Nuclear Medicine, 2021, 62, 60S-72S.	5.0	19
24	Restaging [18F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance. Journal of the American Academy of Dermatology, 2020, 82, 878-886.	1.2	6
25	First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of Nuclear Medicine, 2020, 61, 512-519.	5.0	170
26	Immune-Directed Molecular Imaging Biomarkers. Seminars in Nuclear Medicine, 2020, 50, 584-603.	4.6	3
27	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. Journal of Clinical Oncology, 2020, 38, 4283-4291.	1.6	40
28	Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3047-3057.	6.4	19
29	Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular Radioimmunotherapy. Journal of Nuclear Medicine, 2020, 61, 662-664.	5.0	3
30	Patient-adapted organ absorbed dose and effective dose estimates in pediatric 18F-FDG positron emission tomography/computed tomography studies. BMC Medical Imaging, 2020, 20, 9.	2.7	10
31	Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine, 2019, 60, 1794-1801.	5.0	29
32	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2112-2137.	6.4	208
33	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan. Clinical Cancer Research, 2019, 25, 6939-6947.	7.0	69
34	Targeted Radioimmunotherapy and Theranostics with Alpha Emitters. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S41-S44.	0.3	18
35	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 7014-7023.	7.0	47
36	⁸⁹Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. Journal of Nuclear Medicine, 2019, 60, 1825-1832.	5.0	38

#	Article	IF	Citations
37	Pharmacokinetics and Biodistribution of a [⁸⁹Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. Molecular Pharmaceutics, 2019, 16, 3083-3090.	4.6	26
38	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of Nuclear Medicine, 2019, 60, 1517-1523.	5.0	38
39	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	2.8	42
40	Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. Journal of Neuro-Oncology, 2019, 143, 101-106.	2.9	17
41	Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma. Nuclear Medicine Communications, 2019, 40, 744-751.	1.1	18
42	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
43	Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 677-685.	6.4	44
44	Patient-specific organ and effective dose estimates in pediatric oncology computed tomography. Physica Medica, 2018, 45, 146-155.	0.7	27
45	Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. Seminars in Hematology, 2018, 55, 22-32.	3.4	31
46	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹Zr-Trastuzumab in Patients with Esophagogastric Cancer. Journal of Nuclear Medicine, 2018, 59, 161-166.	5.0	96
47	Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. Journal of Nuclear Medicine, 2018, 59, 147-153.	5.0	96
48	A phase II study of radioimmunotherapy with intraventricular ¹³¹Iâ€3F8 for medulloblastoma. Pediatric Blood and Cancer, 2018, 65, e26754.	1.5	46
49	Longâ€"Half-Life ⁸⁹Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. Journal of Nuclear Medicine, 2018, 59, 399-402.	5.0	9
50	I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Research, 2018, 8, 20.	2.5	17
51	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncology, The, 2018, 19, 1040-1050.	10.7	201
52	Failure of MIBG scan to detect metastases in SDHBâ€mutated pediatric metastatic pheochromocytoma. Pediatric Blood and Cancer, 2017, 64, e26549.	1.5	10
53	Norepinephrine Transporter as a Target for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 39S-53S.	5.0	67
54	Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy. Clinical Nuclear Medicine, 2017, 42, 741-748.	1.3	17

#	Article	IF	Citations
55	A comparison of pediatric and adult CT organ dose estimation methods. BMC Medical Imaging, 2017, 17, 28.	2.7	40
56	The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature. American Journal of Roentgenology, 2017, 209, 182-186.	2.2	1
57	Acute myeloid leukemia therapy elicits durable complete response in chemoradioâ€resistant metastatic paraganglioma. Pediatric Blood and Cancer, 2017, 64, e26314.	1.5	2
58	Feasibility of Administering High-Dose¹³¹I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms. Pediatric Blood and Cancer, 2016, 63, 801-807.	1.5	17
59	Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. BMC Medical Imaging, 2016, 16, 41.	2.7	122
60	I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma. Seminars in Nuclear Medicine, 2016, 46, 203-214.	4.6	52
61	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptorâ€“Axis Imaging. Journal of Nuclear Medicine, 2016, 57, 73S-78S.	5.0	16
62	First-in-Human Imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine, 2016, 57, 1858-1864.	5.0	116
63	Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. American Journal of Roentgenology, 2016, 207, 661-670.	2.2	29
64	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of Nuclear Medicine, 2016, 57, 231-237.	5.0	17
65	Molecular Imaging of Biomarkers in Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 53S-59S.	5.0	56
66	Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. Journal of Neuro-Oncology, 2015, 123, 245-249.	2.9	22
67	PET Imaging of Breast Cancer. PET Clinics, 2015, 10, 159-195.	3.0	21
68	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285.	7.0	163
69	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28.	2.5	63
70	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1700-1706.	6.4	13
71	Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That AffectÂOutcomes. Clinical Colorectal Cancer, 2015, 14, 296-305.	2.3	40
72	89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2093-2105.	6.4	130

#	Article	IF	Citations
73	Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer. Journal of Nuclear Medicine, 2013, 54, 1697-1702.	5.0	64
74	Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 31-31.	1.6	8
75	¹²⁴I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET. Journal of Nuclear Medicine, 2011, 52, 1878-1885.	5.0	47
76	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML). Blood, 2011, 118, 768-768.	1.4	27
77	Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. Journal of Neuro-Oncology, 2010, 97, 409-418.	2.9	208
78	Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. Gynecologic Oncology, 2010, 117, 59-64.	1.4	85
79	Sequential Cytarabine and Î±-Particle Immunotherapy with Bismuth-213â€“Lintuzumab (HuM195) for Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5303-5311.	7.0	234
80	Transient sialoadenitis: A complication of ¹³¹Iâ€metaiodobenzylguanidine therapy. Pediatric Blood and Cancer, 2008, 50, 1271-1273.	1.5	36
81	The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by 111Indium-labeled humanized monoclonal antibody 3S193. European Journal of Radiology, 2008, 67, 292-299.	2.6	6
82	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using ¹¹¹In-J591: Lesion Detectability and Dosimetric Projections for ⁹⁰Y Radioimmunotherapy. Journal of Nuclear Medicine, 2008, 49, 1066-1074.	5.0	76
83	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. Clinical Cancer Research, 2007, 13, 2707-2713.	7.0	73
84	Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncology, The, 2007, 8, 304-310.	10.7	370
85	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 910-910.	1.4	15
86	Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. Journal of Nuclear Medicine, 2006, 47, 1202-8.	5.0	88
87	Pilot Trial of Unlabeled and Indium-111â€“Labeled Antiâ€“Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. Clinical Cancer Research, 2005, 11, 7454-7461.	7.0	120
88	Oncologic imaging in gynecologic malignancies. Journal of Nuclear Medicine, 2005, 46, 1842-50.	5.0	42
89	Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET. American Journal of Roentgenology, 2004, 183, 1143-1147.	2.2	54
90	Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 1790-1790.	1.4	12

#	Article	IF	Citations
91	Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.. Blood, 2004, 104, 5113-5113.	1.4	0
92	Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. Journal of Nuclear Medicine, 2004, 45, 1358-65.	5.0	143
93	New strategies in radioimmunotherapy for lymphoma. Current Oncology Reports, 2003, 5, 364-371.	4.0	7